Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma

Qian-Ying Zhu; Xiang-Wei Kong; Cong Sun; Shang-Hang Xie; Allan Hildesheim; Su-Mei Cao; Mu-Sheng Zeng

doi:10.1128/mSphere.00901-20

DOI: 10.1128/mSphere.00901-20

Article Figures & Data

Figures

Tables
Supplemental Material

Open in new tab
Download powerpoint
FIG 1
Plasma neutralization titers of nasopharyngeal carcinoma cases and control groups. (A) Neutralizing ability against Epstein-Barr virus (EBV) infection of epithelial cells represented by 50% inhibitory dilution (ID₅₀) in nasopharyngeal carcinoma (NPC) cases, high-risk healthy controls (HC), and low-risk healthy controls (LC). (B) Neutralizing ability (ID₅₀) against EBV infection of B cells in NPC cases, HC, and LC. (C) Correlation between the neutralizing ability (ID₅₀) against EBV infection of B cells and that of epithelial cells. For definitions of significance symbols for all figures, see Materials and Methods.
Open in new tab
Download powerpoint
FIG 2
Glycoprotein antibody levels of nasopharyngeal carcinoma cases and control groups. (A) Analysis of the IgG-specific antibody levels targeting Epstein-Barr virus (EBV) glycoproteins in nasopharyngeal carcinoma (NPC) cases, high-risk healthy controls (HC), and low-risk healthy controls (LC). (B) Analysis of the IgA-specific antibody levels targeting EBV glycoproteins in NPC cases, HC, and LC.
Open in new tab
Download powerpoint
FIG 3
Correlation between plasma neutralization titers and glycoprotein antibody levels. (A) Correlation between neutralizing ability against Epstein-Barr virus (EBV) infection of epithelial cells represented by 50% inhibitory dilution (ID₅₀) and the IgG response against gH/gL, gB, gp350, and gp42. (B) Correlation between neutralizing ability against EBV infection of epithelial cells (ID₅₀) and the IgA response against gH/gL, gB, gp350, and gp42. (C) Correlation between neutralizing ability against EBV infection of B cells (ID₅₀) and the IgG response against gH/gL, gB, gp350, and gp42. (D) Correlation between neutralizing ability against EBV infection of B cells (ID₅₀) and the IgA response against gH/gL, gB, gp350, and gp42.

TABLE 1
Characteristics of study participants^a
↵a Abbreviations: NPC, nasopharyngeal carcinoma; HC, high-risk healthy controls; LC, low-risk healthy controls.

Supplemental Material

Figures
Tables

FIG S1
Screening analyses of collected plasma samples from nasopharyngeal carcinoma cases and control groups. (A) Analysis of the IgA response to Epstein-Barr virus (EBV) capsid antigen (VCA) of samples from nasopharyngeal carcinoma (NPC) cases, high-risk healthy controls (HC), and low-risk healthy controls (LC). (B) Analysis of the IgA response to EBV nuclear antigen-1 (EBNA1) of samples from NPC cases, HC, and LC. (C) Analysis of LogitP (P) value of samples from NPC cases, HC, and LC. P = −3.934 + 2.203 × VCA/IgA + 4.797 × EBNA1/IgA. Download FIG S1, TIF file, 0.4 MB.
Copyright © 2020 Zhu et al.
This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.
FIG S2
Purification of EBV glycoproteins. (A) Purified EBV glycoproteins were separated by reducing and nonreducing SDS-PAGE and stained with Coomassie brilliant blue. (B) The binding between murine monoclonal antibodies and EBV glycoproteins was detected by ELISA. Download FIG S2, TIF file, 2.0 MB.
Copyright © 2020 Zhu et al.
This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.
FIG S3
Correlation between viral loads and glycoprotein antibody levels. (A) Correlation between relative viral load in epithelial cells and the IgG response against gH/gL, gB, gp350, and gp42. (B) Correlation between relative viral load in B cells and the IgG response against gH/gL, gB, gp350, and gp42. Download FIG S3, TIF file, 0.9 MB.
Copyright © 2020 Zhu et al.
This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.